Real-life comparison between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
P. Cameli (Siena (SI), Italy), L. Bergantini (Siena (SI), Italy), M. D'Alessandro (Siena (SI), Italy), R. Refini (Siena (SI), Italy), M. Pieroni (Siena (SI), Italy), V. Alonzi (Siena (SI), Italy), P. Sestini (Siena (SI), Italy), E. Bargagli (Siena (SI), Italy)
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Cameli (Siena (SI), Italy), L. Bergantini (Siena (SI), Italy), M. D'Alessandro (Siena (SI), Italy), R. Refini (Siena (SI), Italy), M. Pieroni (Siena (SI), Italy), V. Alonzi (Siena (SI), Italy), P. Sestini (Siena (SI), Italy), E. Bargagli (Siena (SI), Italy). Real-life comparison between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis. 460
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: